Beard SM - Search Results

1

Cost-effectiveness of febuxostat in chronic gout.

Beard SM, von Scheele BG, Nuki G, Pearson IV. Beard SM, et al. Eur J Health Econ. 2014 Jun;15(5):453-63. doi: 10.1007/s10198-013-0486-z. Epub 2013 May 30. Eur J Health Econ. 2014. PMID: 23719971

2

Economic evaluation in chronic pain: a systematic review and de novo flexible economic model.

Sullivan W, Hirst M, Beard S, Gladwell D, Fagnani F, López Bastida J, Phillips C, Dunlop WC. Sullivan W, et al. Eur J Health Econ. 2016 Jul;17(6):755-70. doi: 10.1007/s10198-015-0720-y. Epub 2015 Sep 16. Eur J Health Econ. 2016. PMID: 26377997 Free PMC article. Review.

3

Cost effectiveness of duloxetine in the treatment of fibromyalgia in the United States.

Beard SM, Roskell N, Le TK, Zhao Y, Coleman A, Ang D, Lawson K. Beard SM, et al. J Med Econ. 2011;14(4):463-76. doi: 10.3111/13696998.2011.586389. Epub 2011 Jun 9. J Med Econ. 2011. PMID: 21651426 Free article.

4

A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany.

Beard SM, Maciver F, Clouth J, Rüther E. Beard SM, et al. Eur J Health Econ. 2006 Sep;7(3):165-72. doi: 10.1007/s10198-006-0347-0. Eur J Health Econ. 2006. PMID: 16896764

5

Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK.

Emery P, Van Keep M, Beard S, Graham C, Miles L, Jugl SM, Gunda P, Halliday A, Marzo-Ortega H. Emery P, et al. Among authors: beard s. Pharmacoeconomics. 2018 Aug;36(8):1015-1027. doi: 10.1007/s40273-018-0675-9. Pharmacoeconomics. 2018. PMID: 29797186 Free PMC article.

6

A Systematic Review of the Economic and Humanistic Burden of Gout.

Shields GE, Beard SM. Shields GE, et al. Among authors: beard sm. Pharmacoeconomics. 2015 Oct;33(10):1029-47. doi: 10.1007/s40273-015-0288-5. Pharmacoeconomics. 2015. PMID: 25969152 Review.

7

Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK.

Beard SM, McCrink L, Le TK, Garcia-Cebrian A, Monz B, Malik RA. Beard SM, et al. Curr Med Res Opin. 2008 Feb;24(2):385-99. doi: 10.1185/030079908x253852. Curr Med Res Opin. 2008. PMID: 18157921

8

A Cost-Utility Analysis of Lisdexamfetamine Versus Atomoxetine in the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Inadequate Response to Methylphenidate.

Zimovetz EA, Beard SM, Hodgkins P, Bischof M, Mauskopf JA, Setyawan J. Zimovetz EA, et al. Among authors: beard sm. CNS Drugs. 2016 Oct;30(10):985-96. doi: 10.1007/s40263-016-0354-3. CNS Drugs. 2016. PMID: 27530525 Free PMC article.

9

A review of cost-effectiveness of varenicline and comparison of cost-effectiveness of treatments for major smoking-related morbidities.

Zimovetz EA, Wilson K, Samuel M, Beard SM. Zimovetz EA, et al. Among authors: beard sm. J Eval Clin Pract. 2011 Apr;17(2):288-97. doi: 10.1111/j.1365-2753.2010.01439.x. Epub 2010 Oct 4. J Eval Clin Pract. 2011. PMID: 21029268 Review.

10

The cost-effectiveness of prophylaxis with valaciclovir in the management of cytomegalovirus after renal transplantation.

Legendre C, Beard SM, Crochard A, Lebranchu Y, Pouteil-Noble C, Richter A, Durand-Zaleski I. Legendre C, et al. Among authors: beard sm. Eur J Health Econ. 2005 Jun;6(2):172-82. doi: 10.1007/s10198-004-0275-9. Eur J Health Econ. 2005. PMID: 15765243

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

30 results

Search Page

Filters